Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InMode Ltd. (NASDAQ:INMD ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Miri Segal - Investor Relations, MS-IR LLC Moshe Mizrahy - Chairman and Chief Executive Officer Michael Kreindel - Chief Technology Officer & Director Yair Malca - Chief Financial Officer Shakil Lakhani - President, North America Spero Theodorou - Chief Medical Officer Rafael Lickerman - VP of Finance Conference Call Participants Q - Joseph Conway Q - Jeff Johnson Operator Good morning and welcome to the InMode Ltd.

InMode Ltd. (INMD) CEO Moshe Mizrahy on Q2 2022 Results - Earnings Call Transcript

InMode's margin is under pressure from multiple points, but it probably won't matter.

2 Potential Headwinds and 2 Potential Tailwinds for InMode Stock in August

YOKNEAM, Israel, July 28, 2022 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2022.

InMode Reports Second Quarter 2022 Financial Results; Record Quarterly Revenue of $113.5M, Represents 30% Year-Over-Year Growth

InMode raised full-year guidance, surprising market participants. We are very pleased with the company's operational development as internationalization progresses and recurring revenues increase.

InMode Set To Outperform Going Forward, We Join The Bull Camp

InMode's growth trajectory belies its low valuation.

This Fierce Growth Stock Is a Monster Value Right Now

YOKNEAM, Israel , July 20, 2022 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer, will present at the Canaccord 42nd Annual Growth Conference on Aug. 11, 2022, at the InterContinental Boston hotel.

InMode to Present at the Canaccord 42nd Annual Growth Conference

Doximity

Shockwave Medical

Here's why investors in InMode, Shockwave Medical, and Doximity are excited about the rest of 2022.

3 Healthcare Stocks That Are Raising Guidance in 2022

Shares of the cosmetic med-tech pioneer are deep in value territory right now.

Is InMode a Good Stock to Buy Now?

Although it has been a tough year so far, INMD stock is now exploding to the upside management raises revenue expectations. The post InMode (INMD) Stock Rises 18% on Record Revenue Expectations appeared first on InvestorPlace.

InMode (INMD) Stock Rises 18% on Record Revenue Expectations

The company is doing better than anyone expected.

Why InMode Stock Popped Today

InMode Ltd (NASDAQ: INMD) expects Q2 sales of $113.0 million - $113.3 million, beating the consensus of $103.13 million. The company sees the adjusted EPS of $0.57 to $0.58, surpassing the consensus of $0.51, with a gross margin of 83% - 85%.

InMode Shares Jump On Better Than Expected Q2 Interim Earnings

Shares of medical technology company InMode Ltd (NASDAQ: INMD) are trading higher Tuesday after the company issued second-quarter guidance above analyst estimates. InMode said that based on preliminary results, the company expects second-quarter revenue to be between $113 million and $113.

Why InMode Stock Is Surging Today

Conference call to be held on Thursday, July 28, 2022, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 12, 2022 /PRNewswire/ -- InMode Ltd.

InMode Expects Record Second Quarter 2022 Financial Results, Revenue Between $113.0-$113.3M, Increasing Full Year 2022 Revenue Guidance to $425-$435M

InMode is trading for a trough valuation, similar to the COVID panic low. The chart looks very bullish from the perspective that a bottom is likely in.

InMode: Asymmetrical Reward Opportunity For The Bulls

InMode has generally been a great success story since its public offering. After a huge boom in 2021 and subsequent bust, valuations look very compelling again.

InMode: Prettier Again

IRVINE, Calif. , June 15, 2022 /PRNewswire/ -- InMode Ltd.

InMode Receives Health Canada Certification of EmpowerRF Women's Wellness Technology

I provide a brief background of InMode and its company's operations, and also the recent sell-off of InMode stock. I explain why investing in InMode could be a good decision at its current valuation by analyzing the company's prospects and historical financial performance.

InMode Stock: Hidden Opportunity

InMode Ltd (NASDAQ:INMD) is a global provider of medical technologies.

Consider This Healthcare Stock to Improve Your Portfolio

Applied Materials

Coinbase

Etsy

Moderna

Target

Stocks often over sell after panicking investors get rid of shares, which eventually leads to the stock bouncing back dramatically. The post 7 Deeply Oversold Stocks to Buy Before They Bounce appeared first on InvestorPlace.

7 Deeply Oversold Stocks to Buy Before They Bounce

InMode had double-digit revenue and net income growth year-over-year. Gross margin remains above 80%, despite the negative impact of the increased shipping costs.

InMode: Growth At A Reasonable Price

YOKNEAM, Israel , May 23, 2022 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer and Yair Malca , Chief Financial Officer, will participate at the UBS Healthcare One-on-One Virtual Day on June 1 st, 2022.

InMode to Participate at the UBS Healthcare One-on-One Virtual Day

Below I explain why InMode has sold off so aggressively since the start of 2022. With $400M of cash on hand, management could repurchase 25% of their float based on InMode's current valuation.

InMode: Management Could Repurchase 25% Of Their Float

InMode's sales and profits have boomed, but you wouldn't know it from the company's share price.

1 Company Disrupting Plastic Surgery, Not Patients

The financial results are solid but investors are still lowering their expectations.

This Is Why InMode Stock Fell 32% in April

InMode Ltd. (NASDAQ:INMD ) Q1 2022 Earnings Conference Call May 2, 2022 8:30 AM ET Company Participants Miri Segal - Investor Relations Moshe Mizrahy - Chairman and Chief Executive Officer Michael Kreindel - Co-Founder and Chief Technology Officer Yair Malca - Chief Financial Officer Shakil Lakhani - President, North America Spero Theodorou - Chief Medical Officer Rafael Lickerman - Vice President, Finance Conference Call Participants Mike Matson - Needham & Company Jeff Johnson - Baird Operator Hello and welcome to the InMode Limited First Quarter 2022 Earnings Results Conference Call.

News for Inmode Ltd Stock (INMD)